No Data
Kura Oncology's Strategic Developments and Partnership With Kyowa Kirin Justify Buy Rating, Despite Initial Stock Dip
Jefferies Adjusts Kyowa Kirin's Price Target to 3,000 Yen From 3,700 Yen, Keeps at Buy
Express News | Kura Oncology Shares Are Trading Lower. The Company Announced It Entered Into a Global Strategic Collaboration With Kyowa Kirin to Develop and Commercialize Ziftomenib
Kura Teams Up With Kyowa Kirin To Develop Ziftomenib, Secures $330 Mln Upfront
Strategic Partnership With Kyowa Kirin Strengthens Kura Oncology's Financial and Commercial Position
Kura Oncology Partners Kyowa Kirin to Advance AML Treatment
No Data
No Data